E-commerce software producer Lockon, backed by a host of Japan-based corporates, is set to go public in Tokyo.

The Novartis-backed prostate cancer drug developer has filed for an initial public offering after raising more than $100m in funding.

Novo-backed Tobira, which is developing treatments for liver disease and HIV among other ailments, cited market conditions as it withdrew from a $60m IPO.

Tencent invested $60m to become IDreamSky's largest shareholder as the mobile game publisher went public priced above its range.

The IdInvest-backed company, which is developing a treatment for tinnitus, has gone public in an underpriced IPO.

The eye disease drug developer raised $102m in an upsized initial public offering as pharmaceutical company Regeneron invested a further $10m.

The Novartis and Eli Lilly-backed developer of antifungal treatments, will seek to advance three of its candidates through clinical trials using the proceeds from the offering.

Eye disease treatment developer Ocular Therapeutix has raised $65m from an initial public offering in which it floated below its range.

The GE-backed radio station and website operator had previously set a range of $14-$16 for the initial public offering.

The Allianz-backed company, which is developing treatments for inner ear disorders, has set the range for its initial public offering between $10 and $12.